Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study.
Christina D ChambersDiana L JohnsonRonghui XuYunjun LuoJanina Lopez-JimenezMargaret P AdamStephen R BraddockLuther K RobinsonKeith VauxKenneth Lyons Jonesnull nullPublished in: PloS one (2019)
Adalimumab exposure in pregnancy compared to diseased unexposed pregnancies was not associated with an increased risk for any of the adverse outcomes examined. Women with rheumatoid arthritis or Crohn's Disease were at increased risk of preterm delivery, irrespective of adalimumab exposure.
Keyphrases
- rheumatoid arthritis
- pregnancy outcomes
- preterm birth
- gestational age
- juvenile idiopathic arthritis
- disease activity
- pregnant women
- low birth weight
- hidradenitis suppurativa
- ulcerative colitis
- ankylosing spondylitis
- interstitial lung disease
- polycystic ovary syndrome
- type diabetes
- systemic lupus erythematosus
- skeletal muscle
- preterm infants
- insulin resistance
- metabolic syndrome